HiDocTechnologies–Mahana Therapeutics: investment, 202403 acquisition €na of Cara Care by Mahana Therapeutics |
2024-03-12 |
Boehringer–Sosei: GPR52 agonists, 202403– collab drug discovery + excl ww license option €25m upfront + €730m milestones plus tiered royalties |
2024-03-11 |
NanoString–Patient Square Capital: investment, 202403– acquisition $220m of substantially all assets as going concern under Bankruptcy Code |
2024-03-10 |
ProteinDistillery–SEVERAL: investment, 202403 seed financing round €15m (incl credits/grants?) led by Green Generation Fund + Startup Family Office |
2024-03-07 |
Merck (DE)–C4 Therapeutics: protein degraders, 202403– license + collab $16m upfront + $740m milestones + royalties discovery of 2 protein degraders |
2024-03-04 |
BRAIN Biotech–Putsch (Recaro): credit, 202402–202609 convertible bond €5m with MP Beteiligungs-GmbH at 6.52% p.a. |
2024-02-29 |
Neobe Therapeutics–SEVERAL: Investment, 202402 financing round $2.34m led by Pioneer Group incl grant from Innovate UK |
2024-02-29 |
Stilla Technologies–SEVERAL: investment, 202402 financing round Series C $26.5m led by CLIIF |
2024-02-22 |
Cresset–Enamine: virtual drug screening, 202402– collab ww applying Ignite virtual screening technology to Enamine REAL Space library |
2024-02-21 |
Cyclize–Aurum Impact: investment, 202402 seed financing round totalling €4.75m incl co-investor Aurum Impact |
2024-02-21 |
Cyclize–High-Tech Gründerfonds: investment, 202402 seed financing round totalling €4.75m incl co-investor HTGF |
2024-02-21 |
Cyclize–OTHER: investment, 202402 seed financing round totalling €4.75m incl high-profile business angels |
2024-02-21 |
Cyclize–PERSON: investment, 202402 seed financing round totalling €4.75m incl business angel Klaus Schäfer |
2024-02-21 |
Cyclize–SEVERAL: investment, 202402 seed financing round €4.75m led by UVC Partners |
2024-02-21 |
Cyclize–TU Munich: investment, 202402 seed financing round totalling €4.75m incl co-investor UnternehmerTUM Funding for Innovators |
2024-02-21 |
Cyclize–UVC Partners: investment, 202402 seed financing round totalling €4.75m incl lead investor UVC Partners |
2024-02-21 |
Waters–Plasmion: ionisation technology, 202402– collab co-marketing/promotion of SICRIT ion source with Waters Acquity QDa + Select Series Cycli IMS |
2024-02-21 |
AZmed–Maison Worms: investment, 202402 financing round Series A totalling €15m incl investor Maison Worms |
2024-02-20 |
AZmed–SEVERAL: investment, 202402 financing round Series A €15m |
2024-02-20 |
AZmed–Teampact Ventures: investment, 202402 financing round Series A totalling €15m incl investor Teampact Ventures |
2024-02-20 |
AZmed–Techstars: investment, 202402 financing round Series A totalling €15m incl investor Techstars |
2024-02-20 |
Bioptimus–SEVERAL: investment, 202402 company emerges with seed financing round $35m led by Sofinnova Partners |
2024-02-20 |
GlycanAge–SEVERAL: investment, 202402 seed financing round €3.9m led by LauncHub Ventures + Kadmos Capital |
2024-02-19 |
MIP Discovery–Calculus Capital: investment, 202402 financing round Series A totalling £7m incl exsiting + co- investor Calculus Capital |
2024-02-19 |
MIP Discovery–Mercia: investment, 202402 financing round Series A totalling £7m incl lead investor Mercia Ventures |
2024-02-19 |
MIP Discovery–OTHER: investment, 202402 financing round Series A totalling £7m incl angel investors |
2024-02-19 |
MIP Discovery–SEVERAL: investment, 202402 financing round Series A £7m led by Mercia Ventures |
2024-02-19 |
Firefly Bio–SEVERAL: investment, 202402c emerges with financing round Series A $94m co-led by Versant Ventures + MPM BioImpact |
2024-02-15 |
Firefly Bio–Versant Ventures: investment, 202402c emerges with financing round Series A totalling $94m incl co-lead investor Versant Venture |
2024-02-15 |
Freenome–Roche: investment, 202402 financing round totalling $254m incl existing + lead investor Roche |
2024-02-15 |
Freenome–SEVERAL: investment, 202402 financing round $254m led by Roche |
2024-02-15 |
Sysmex–SAFIA Technologies: mycotoxin immunoassays, 202402– distribution ww of tests for food/agri by Sysmex Partec using SAFIA tech + flow cytometry |
2024-02-15 |
Earlybird–Barmer: investment, 202402 final closing of new Earlybird Health Fund totalling €173m incl investor Barmer |
2024-02-14 |
Earlybird–SEVERAL: investment, 202402 final closing of new Earlybird Health Fund at €173m |
2024-02-14 |
Earlybird–United Kingdom (govt): investment, 202402 final closing of new Earlybird Health Fund totalling €173m incl investor British Patient Capital |
2024-02-14 |
Newcells Biotech–Mercia: investment, 202402 financing round totalling £2.35m incl existing investor Mercia Ventures |
2024-02-14 |
Newcells Biotech–Northstar Ventures: investment, 202402 financing round totalling £2.35m incl existing investor Northstar Ventures |
2024-02-14 |
Newcells Biotech–SEVERAL: investment, 202402 financing round £2.35m from existing investors Mercia Ventures + Northstar Ventures |
2024-02-14 |
BMS–Roivant: molecular glue degraders, 202402– strategic collab up to $674m discovery of small-molecule molecular glues by VantAI against BMS targets |
2024-02-13 |
CRISPR Therapeutics–EcoR1 Capital: investment, 202402 registered direct offering totalling $280m incl new + co-lead investor EcoR1 Capital |
2024-02-13 |
CRISPR Therapeutics–SEVERAL: investment, 202402 registered direct offering $280m at $71.5/share led by EcoR1 Capital + SR One |
2024-02-13 |
CRISPR Therapeutics–SR One: investment, 202402 registered direct offering totalling $280m incl co-lead investor SR One |
2024-02-13 |
Roche–PathAI: AI-based diagnostics, 202402– collab expansion excl developm of AI-enabled ditial patholoty algorythms for CDx with RTD |
2024-02-13 |
Amply Discovery–SEVERAL: investment, 2024Q2 seed financing round £1.4m PLANNED NOT YET REALISED 2/24 |
2024-02-12 |
Amply Discovery–United Kingdom (govt): grant, 202402c grant £835k from Innovate UK + Innosuisse to develop RNAi therapy for AML |
2024-02-12 |
Amply Discovery–United Kingdom (govt): grant, 202402c Innovate UK grant £602k to develop inhaled antimicrobial therapies for MDR lung infections |
2024-02-12 |
BugBiome–Cambridge Angels: investment, 202402 pre-seed financing round totalling £310k incl investor Cambridge Angels |
2024-02-12 |
BugBiome–Discovery Park: investment, 202402 pre-seed financing round totalling £310k incl investor Discovery Park Ventures |
2024-02-12 |
BugBiome–SEVERAL: investment, 202402 pre-seed financing round £310k from Cambridge Angels + Discovery Park Ventures |
2024-02-12 |
BugBiome–United Kingdom (govt): grant, 202402– Innovate UK grant £330k to identify methods to control aphids in crop protection |
2024-02-12 |
Sensorion–Aquilo Capital: investment, 202402 reserved offering totalling €50.5m incl new investor Aquilo Capital |
2024-02-09 |
Sensorion–Invus Group: investment, 202402 reserved offering totalling €50.5m incl existing investor Invus Group |
2024-02-09 |
Sensorion–Redmile Group: investment, 202402 reserved offering totalling €50.5m incl existing investor Redmile Group |
2024-02-09 |
Sensorion–SEVERAL: investment, 202402 reserved offering €50.5m with 88.6m new ordinary shares at €0.57/share to existing + new investors |
2024-02-09 |
Sensorion–Sofinnova: investment, 202402 reserved offering totalling €50.5m incl existing investor Sofinnova Partners |
2024-02-09 |
GenSight Biologics–Heights Capital: investment, 202402 capital increase totalling €5m incl €0.25m from new investor CVI Investmens Inc |
2024-02-08 |
GenSight Biologics–Invus Group: investment, 202402 capital increase totalling €5m incl €1.75m from existing investor Invus Public Equities LP |
2024-02-08 |
GenSight Biologics–SEVERAL: investment, 202402 capital increase €5m (€4.7m net) with 13.1m new shares at €0.38/share |
2024-02-08 |
GenSight Biologics–Sofinnova: investment, 202402 capital increase totalling €5m incl €2m from existing investor Sofinnova Crossover I SLP |
2024-02-08 |
GenSight Biologics–Univ Pittsburgh: investment, 202402 capital increase totalling €5m incl existing investor UPMC Enterprises |
2024-02-08 |
Zetta Genomics–Apex Ventures: investment, 202402 2nd seed financing round expansion totalling £1.8m incl existing investor Apex Ventures |
2024-02-08 |
Zetta Genomics–Nina Capital: investment, 202402 2nd seed financing round expansion totalling £1.8m incl existing investor Nina Capital |
2024-02-08 |
Zetta Genomics–SEVERAL: investment, 202402 2nd seed financing round expansion by £1.8m to total of £3.7m |
2024-02-08 |
Zetta Genomics–Univ Cambridge: investment, 202402 2nd seed financing round expansion totalling £1.8m incl existing investor Univ Cambridge |
2024-02-08 |
Zetta Genomics–Werfen: investment, 202402 2nd seed financing round expansion totalling £1.8m incl new investor We Venture Capital |
2024-02-08 |
Sablebio–Episode 1 Ventures: investment, 202402 pre-seed financing round totalling £1.5m incl lead investor Episode 1 Ventures |
2024-02-06 |
Sablebio–PERSON: investment, 202402 pre-seed financing round totalling £1.5m incl co-investor Siddhant Jayakumar |
2024-02-06 |
Sablebio–Seedcamp: investment, 202402 pre-seed financing round totalling £1.5m incl co-investor Seedcamp |
2024-02-06 |
Sablebio–SEVERAL: investment, 202402 pre-seed financing round £1.5m led by Episode 1 Ventures |
2024-02-06 |
Incyte–MorphoSys: tafasitamab, 202402 acquistion ww excl rights by Incyte for $25m for remaining interest in product |
2024-02-05 |
MorphoSys–Novartis: investment, 202402– acquisition of MorphoSys voluntary public takeover offer €2.7b in cash at €68/share |
2024-02-05 |
Sensorion–Institut Pasteur: gene therapy, 202401–202812 collab framework agreem extension incl license options for gene therapies for ear diseases |
2024-02-05 |
Silence Therapeutics–5AM Ventures: investment, 202402 private placement totalling $120m incl investor 5AM Ventures |
2024-02-05 |
Silence Therapeutics–Column Group: investment, 202402 private placement totalling $120m incl investor TCGX |
2024-02-05 |
Silence Therapeutics–Frazier: investment, 202402 private placement totalling $120m incl investor Fazier Life Sciences |
2024-02-05 |
Silence Therapeutics–Logos Capital: investment, 202402 private placement totalling $120m incl investor Logos Capital |
2024-02-05 |
Silence Therapeutics–Nextech: investment, 202402 private placement totalling $120m incl investor Nextech Invest Ltd |
2024-02-05 |
Silence Therapeutics–Redmile Group: investment, 202402 private placement totalling $120m incl investor Redmile Group |
2024-02-05 |
Silence Therapeutics–SEVERAL: investment, 202402 private placement $120m mit 5.7m ADSs at $12/ADS |
2024-02-05 |
Silence Therapeutics–Vivo Capital: investment, 202402 private placement totalling $120m incl investor Vivo Capital |
2024-02-05 |
Aqemia–Elaia Partners: investment, 202401 financing round Series A extension totalling €30m incl existing + co-investor Elaia |
2024-01-30 |
Aqemia–Eurazeo: investment, 202401 financing round Series A extension totalling €30m incl existing + co-investor Eurazeo |
2024-01-30 |
Aqemia–France (govt): investment, 202401 financing round Series A extension totalling €30m incl existing + co-investor Bpifrance Large Venture |
2024-01-30 |
Aqemia–SEVERAL: investment, 202401 financing round Series A extension €30m led by Wendel Growth bringing total Series A to €60m |
2024-01-30 |
Aqemia–Wendel: investment, 202401 financing round Series A extension totalling €30m incl new + lead investor Wendel Growth |
2024-01-30 |
Enterprise Therapeutics–SEVERAL: investment, 202401 financing round Series B follow-on £26m led by Panakès Partners |
2024-01-30 |
TenAces Biosciences–Aion Labs: investment, 202401 founding investor Aion Labs announces TenAces |
2024-01-30 |
Rhineland-Palatinate (govt)–Axa: business park management, 202401– collab of Kadans Science Partner Deutschland + Technologiezentrum Mainz for biotech |
2024-01-29 |
Affluent Medical–SEVERAL: investment, 2021401 bridge financing €3.5m with 2.24m new ordinary shares at €1.56/share from existing key shareholders |
2024-01-26 |
Chemspeed–Bruker: investment, 202401– acquisition €na of Chemspeed Technology AG by Bruker |
2024-01-25 |
Melio Health–Inizio: public relations, 202401 service existent to IMU Biosciences by Medistrava Consulting |
2024-01-24 |
Melio Health–LifeX Ventures: investment, 202401 financing round Series A totalling £11.5m of IMU Biosciences incl co-investor LifeX Ventures |
2024-01-24 |
Melio Health–Molten Ventures: investment, 202401 financing round Series A totalling £11.5m of IMU Biosciences incl lead investor Molten Ventures |
2024-01-24 |
Melio Health–OTHER: investment, 202401 financing round Series A totalling £11.5m of IMU Biosciences incl individuals as co-investors |
2024-01-24 |
Melio Health–SEVERAL: investment, 202401 financing round Series A £11.5m led by Molten Ventures |
2024-01-24 |
BioLizard–MC Services: public relations, 202401 service existent by MC Services |
2024-01-23 |
Sano Genetics–Episode 1 Ventures: investment, 202401 financing round totalling $11.4m incl existing + co-investor Episode 1 |
2024-01-22 |
Sano Genetics–MMC Ventures: investment, 202401 financing round totalling $11.4m incl existing + co-investor MMC Ventures |
2024-01-22 |
Sano Genetics–Plural: investment, 202401 financing round totalling $11.4m incl lead investor Plural |
2024-01-22 |
Sano Genetics–Seedcamp: investment, 202401 financing round totalling $11.4m incl existing + co-investor Seedcamp |
2024-01-22 |